Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
June 12, 2025 12-1pm EDT University City Science Center 3675 Market Street Room:Qu4a Philadelphia, PA 19104 Join Inotiv for a free lunch and learn seminar focused on optimizi...
June 16-19, 2025 Lisbon, Portugal Booth #30 EACR 2025 is a four day congress dedicated to basic, preclinical, and translational cancer research across a wide breadth of topics. It ...
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
General Toxicology
Histology
Pathology
DMPK
Consulting
Research Models
Research Model Services
Teklad Diet and Bedding
